Amneal Pharmaceuticals (AMRX) Net Margin (2018 - 2026)

Amneal Pharmaceuticals' Net Margin history runs 9 years deep, the most recent figure standing at 10.8% for Q1 2026.

• On a quarterly basis, Net Margin rose 726.0% year-over-year to 10.8% in Q1 2026; TTM through Mar 2026 was 5.95%, a 481.0% increase from a year earlier, with the FY2025 full-year figure at 4.24%, up 842.0% from the prior year.
• Net Margin advanced to 10.8% in Q1 2026 per AMRX's latest filing, from 6.09% in the prior quarter.
• Across five years, Net Margin topped out at 10.8% in Q1 2026 and bottomed at 21.6% in Q2 2022.
• The 5-year median for Net Margin is 1.56% (2023), against an average of 1.14%.
• Across the five-year window, Net Margin tumbled 2431 bps in 2022 and jumped 2359 bps in 2023, its largest moves.
• Year by year, Net Margin stood at 0.27% in 2022, then sank by 5940 bps to 15.99% in 2023, then surged by 82 bps to 2.84% in 2024, then jumped by 314 bps to 6.09% in 2025, then soared by 77 bps to 10.8% in 2026.
• Per Business Quant, the three latest AMRX Net Margin figures stand at 10.8% (Q1 2026), 6.09% (Q4 2025), and 2.31% (Q3 2025).